Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer's Disease

Stock Information for Annovis Bio Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Annovis Bio Inc.

NeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial
Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study
Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results
Annovis Announces Two Presentations at the AD/PD(TM) 2026 International Conference
Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients
Annovis to Host Corporate Update Webinar on January 28, 2026
Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group
Annovis Announces Two Presentations at the CTAD 2025 Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.